CSIMarket
 


Regenxbio Inc   (RGNX)
Other Ticker:  
 
 

RGNX's Capital Expenditures Growth by Quarter and Year

Regenxbio Inc 's Capital Expenditures results by quarter and year




RGNX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 5.47 14.61 6.07
III Quarter September 1.44 5.05 18.70 3.28
II Quarter June 2.58 9.24 19.84 4.63
I Quarter March 4.82 10.97 31.02 1.03
FY   8.84 30.73 84.17 15.01



RGNX Capital Expenditures third quarter 2023 Y/Y Growth Comment
Regenxbio Inc reported drop in Capital Expenditures in the third quarter 2023 by -71.5% to $ 1.44 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Regenxbio Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 220.43%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 68 other companies have achieved higher Capital Expenditures growth. While Regenxbio Inc ' s Capital Expenditures meltdown of -71.5% ranks overall at the positon no. 2729 in the third quarter 2023.




RGNX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -62.56 % 140.69 % 126.49 %
III Quarter September -71.5 % -72.99 % 470.12 % -41.01 %
II Quarter June -72.08 % -53.43 % 328.51 % 88.21 %
I Quarter March -56.06 % -64.64 % 2911.65 % -78.94 %
FY   - -63.49 % 460.76 % -3.72 %

Financial Statements
Regenxbio Inc 's third quarter 2023 Capital Expenditures $ 1.44 millions RGNX's Income Statement
Regenxbio Inc 's third quarter 2022 Capital Expenditures $ 5.05 millions Quarterly RGNX's Income Statement
New: More RGNX's historic Capital Expenditures Growth >>


RGNX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 8.32 % -21.87 % 85.06 %
III Quarter September -44.22 % -45.35 % -5.75 % -29.16 %
II Quarter June -46.47 % -15.77 % -36.04 % 349.51 %
I Quarter March -11.88 % -24.91 % 411.04 % -61.57 %
FY (Year on Year)   - -63.49 % 460.76 % -3.72 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #69
Healthcare Sector #432
Overall #2729

Capital Expenditures Y/Y Growth Statistics
High Average Low
3364.84 % 220.43 % -79.76 %
(Dec 31 2016)   (Sep 30 2017)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #69
Healthcare Sector #432
Overall #2729
Capital Expenditures Y/Y Growth Statistics
High Average Low
3364.84 % 220.43 % -79.76 %
(Dec 31 2016)   (Sep 30 2017)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Regenxbio Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
366.89 % 35.44 % -73.21 %
(Dec 31 2017)  


RGNX's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Regenxbio Inc disclosed fall in Capital Expenditures sequentially by -44.22% to $ 1.44 millions, from $ 2.58 millions achived in the previous reporting period.

When you analyse present shortcoming at the III. Quarter, you must assume, that frequently III. Quarter performance occur weaker in contrast to the second quarter

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Regenxbio Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2531.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #412
Overall #2531
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #412
Overall #2531
Capital Expenditures Q/Q Growth Statistics
High Average Low
366.89 % 35.44 % -73.21 %
(Dec 31 2017)  


RGNX's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Regenxbio Inc disclosed fall in Capital Expenditures sequentially by -44.22% to $ 1.44 millions, from $ 2.58 millions achived a quarter before.

This is not important concern, as III. Quarter Capital Expenditures always seem to dip in the III. Quarter Colin M. Martin, Biotechnology & Pharmaceuticals industry observer wrote.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Regenxbio Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2531.


Regenxbio Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 14.30 $ 17.92 $ 24.58 $ 30.72 $ 39.87
Y / Y Capital Expenditures Growth (TTM) -64.12 % -66.52 % -61.67 % -63.5 % -47.29 %
Year on Year Capital Expenditures Growth Overall Ranking # 1397 # 1473 # 301 # 48 # 2157
Seqeuential Capital Expenditures Change (TTM) -20.16 % -27.1 % -20.01 % -22.94 % -25.5 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1253 # 1561 # 900 # 1044 # 2445




Cumulative Capital Expenditures growth Comment
Regenxbio Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Regenxbio Inc 's annual Capital Expenditures drop would be -64.12% year on year to $14 millions.

In the Healthcare sector 201 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1397, from total ranking in previous quarter at 1473.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
551 %
72.67 %
-66.52 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 202
Overall # 1397

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
551 %
72.67 %
-66.52 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 175
S&P 500 # 1253
Cumulative Capital Expenditures growth Comment
Regenxbio Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Regenxbio Inc 's annual Capital Expenditures drop would be -64.12% year on year to $14 millions.

In the Healthcare sector 201 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1397, from total ranking in previous quarter at 1473.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
551 %
72.67 %
-66.52 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 202
Overall # 1397

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
551 %
72.67 %
-66.52 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 175
S&P 500 # 1253




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
RGNX's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for RGNX's Competitors
Capital Expenditures Growth for Regenxbio Inc 's Suppliers
Capital Expenditures Growth for RGNX's Customers

You may also want to know
RGNX's Annual Growth Rates RGNX's Profitability Ratios RGNX's Asset Turnover Ratio RGNX's Dividend Growth
RGNX's Roe RGNX's Valuation Ratios RGNX's Financial Strength Ratios RGNX's Dividend Payout Ratio
RGNX's Roa RGNX's Inventory Turnover Ratio RGNX's Growth Rates RGNX's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com